Skip to main content
. Author manuscript; available in PMC: 2009 Jun 1.
Published in final edited form as: Dev Dyn. 2008 Jun;237(6):1746–1753. doi: 10.1002/dvdy.21572

Figure 6.

Figure 6

Bosentan-induced delay of CCS maturation. Treatment with ET receptor antagonist results in decreased angle value of the epicardial breakthrough, a parameter that increases linearly with development from 50 to 150 degrees between Stages 29–35 (Gurjarpadhye et al., 2007).